← Back to patent-cliff list
CAS 5909-24-0
ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate
Codes：PALB-014、AVAN-004
Application context (from source-drug indications)
乳腺癌哌柏西利勃起功能障碍阿伐那非
Source drugs (routes using this intermediate)
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
cyclopentanamine→tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate→tert-butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate→ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate→ethyl 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carboxylate→(4-(cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol→4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde→1-(4-(cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)ethanol→1-(4-(cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)ethan-1-one→ethyl 2-(diethoxyphosphoryl)acetate→8-cyclopentyl-5-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one→6-bromo-8-cyclopentyl-5-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one→2-((4-nitrophenyl)sulfonyl)-3-phenyl-1,2-oxaziridine→6-bromo-8-cyclopentyl-5-methyl-2-(methylsulfinyl)pyrido[2,3-d]pyrimidin-7(8H)-one→tributyl(1-ethoxyvinyl)stannane→tert-butyl 4-(6-((8-cyclopentyl-6-(1-ethoxyvinyl)-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate
diethyl 2-(ethoxymethylene)malonate→methyl carbamimidothioate→ethyl 4-hydroxy-2-(methylthio)pyrimidine-5-carboxylate→ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate→(3-chloro-4-methoxyphenyl)methanamine hydrochloride→ethyl 4-((3-chloro-4-methoxybenzyl)amino)-2-(methylthio)pyrimidine-5-carboxylate→ethyl 4-((3-chloro-4-methoxybenzyl)amino)-2-(methylsulfinyl)pyrimidine-5-carboxylate→(S)-pyrrolidin-2-ylmethanol→ethyl (S)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidine-5-carboxylate→(S)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidine-5-carboxylic acid→pyrimidin-2-ylmethanamine hydrochloride
ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate→ethyl 4-((3-chloro-4-methoxybenzyl)amino)-2-(methylthio)pyrimidine-5-carboxylate→(S)-pyrrolidin-2-ylmethanol→(3-chloro-4-methoxyphenyl)methanamine→4-((3-chloro-4-methoxybenzyl)amino)-2-(methylthio)pyrimidine-5-carboxylic acid→pyrimidin-2-ylmethanamine→4-((3-chloro-4-methoxybenzyl)amino)-2-(methylthio)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide→4-((3-chloro-4-methoxybenzyl)amino)-2-(methylsulfinyl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | PD 0332991 HCl Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.